Organization (Other)
IBSA FARMACEUTICI ITALIA S.R.L.
ClinicalTrials.gov lists IBSA FARMACEUTICI ITALIA S.R.L. as lead sponsor of 11 trials. It has 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers IBSA FARMACEUTICI ITALIA S.R.L.: 11 lead-sponsored trials and 1 legal-entity registration.
Disease areas (10)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Iron Deficiencies | 2 |
| Anemia | 1 |
| Anemia, Iron-Deficiency | 1 |
| Cutis Laxa | 1 |
| Dyslipidemias | 1 |
Showing 5 of 10 disease areas.
Trials by start year as sponsor or collaborator (4)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 3 |
| 2023 | 4 |
| 2022 | 3 |
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (1)
| Drug | Trials |
|---|---|
| Sodium Hyaluronate | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 67% hit target (n=6) | 40% on time (n=5) |
Journals published in (1)
| Journal | Publications |
|---|---|
| Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] | 1 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 4 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 23 | 2026-08-13 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| IBSA Farmaceutici Italia Srl | Lodi (San Grato) Lombardy, IT | EMA, FDA | |
| Ibsa Farmaceutici Italia S.r.l. | Cassina De' Pecchi, IT | EMA |
Latest dated events (38)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-13 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-07-10 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-05-06 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-04-21 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-02-10 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 38 events.
Biomarker capability evidence (2)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| IPP | Trial sponsor | Named in trial exclusion criteria |
| IPP | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.